News

The company received notification from French pharmaceutical regulatory agency l’Agence National de Sécurité du Médicament et des produits de santé (ANSM) to suspend manufacturing within the site. Catalent

Sparsentan, also known as RE-021, is an investigational therapeutic agent which acts as a potent angiotensin receptor blocker, and a selective endothelin receptor antagonist, with in vitro selectivity

Under the collaboration, Emerson’s DeltaV distributed control system will be integrated with GE’s technologies to manufacture monoclonal antibodies, vaccines and other biologics. The initial DeltaV-driven GE Healthcare installation

Darzalex is a monoclonal antibody that is designed to help the body’s immune system fight cancer cells. In clinical studies involving over 140 people, Darzalex reduced the cancer’s

The 455-patient randomized, double-masked, vehicle-controlled, dose-ranging study (ClinicalTrials.gov Identifier: NCT02254265) was conducted at 28 investigational sites in the U.S. In the study, both concentrations (0.05% and 0.09%) of

Epic Sciences president and CEO Murali Prahalad said: "Successful treatment of cancer depends on understanding the heterogeneity of the patient’s tumor burden and the driving genetic alterations behind

HEALOS will evaluate the efficacy, safety and tolerability of single dose intratympanic injections of AM-111 in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL; a.k.a. "sudden deafness").

The Orphan Drug Designation has been granted for the combination of two active ingredients of AB569: sodium nitrite and ethylenediaminetetraacetic acid. AB569 is to be administered to patients

Mylan offered $75 in cash and 2.3 ordinary shares for each Perrigo share. Perrigo has however called the Mylan proposal inadequate. Following the offer expiry, Mylan executive chairman